Albert Yu has been appointed chief medical officer of New York-based Petra Pharma. Yu’s experience includes executive roles at Calistoga Pharmaceuticals, Omeros (NASDAQ: [[ticker:OMER]]), and Icos. Petra, which is developing drugs to treat cancer and other diseases by targeting the phosphoinositide signaling pathway, emerged in 2016 with a $48 million Series A round of funding.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
